These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 15239132)

  • 21. Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk.
    Serrano-Fernández P; Debniak T; Górski B; Bogdanova N; Dörk T; Cybulski C; Huzarski T; Byrski T; Gronwald J; Wokołorczyk D; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2009 Sep; 117(1):161-5. PubMed ID: 19030985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
    Näslund-Koch C; Nordestgaard BG; Bojesen SE
    J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations.
    Kaufman B; Laitman Y; Gronwald J; Winqvist R; Irmejs A; Lubinski J; Pylkäs K; Gardovskis J; Miklasevics E; Friedman E
    Fam Cancer; 2009; 8(4):473-8. PubMed ID: 19609724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype.
    van Puijenbroek M; van Asperen CJ; van Mil A; Devilee P; van Wezel T; Morreau H
    J Pathol; 2005 Jun; 206(2):198-204. PubMed ID: 15818573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel founder CHEK2 mutation is associated with increased prostate cancer risk.
    Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J
    Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
    Vahteristo P; Bartkova J; Eerola H; Syrjäkoski K; Ojala S; Kilpivaara O; Tamminen A; Kononen J; Aittomäki K; Heikkilä P; Holli K; Blomqvist C; Bartek J; Kallioniemi OP; Nevanlinna H
    Am J Hum Genet; 2002 Aug; 71(2):432-8. PubMed ID: 12094328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
    Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
    Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limited relevance of the CHEK2 gene in hereditary breast cancer.
    Dufault MR; Betz B; Wappenschmidt B; Hofmann W; Bandick K; Golla A; Pietschmann A; Nestle-Krämling C; Rhiem K; Hüttner C; von Lindern C; Dall P; Kiechle M; Untch M; Jonat W; Meindl A; Scherneck S; Niederacher D; Schmutzler RK; Arnold N
    Int J Cancer; 2004 Jun; 110(3):320-5. PubMed ID: 15095295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: not present in the Chinese familial breast cancer population.
    Chen W; Yurong S; Liansheng N
    Adv Ther; 2008 May; 25(5):496-501. PubMed ID: 18484200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of familial male breast cancer for germline mutations in CHEK2.
    Sodha N; Wilson C; Bullock SL; Phillimore H; Houlston RS; Eeles RA
    Cancer Lett; 2004 Nov; 215(2):187-9. PubMed ID: 15488637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
    Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
    Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.
    Novak DJ; Chen LQ; Ghadirian P; Hamel N; Zhang P; Rossiny V; Cardinal G; Robidoux A; Tonin PN; Rousseau F; Narod SA; Foulkes WD
    BMC Cancer; 2008 Aug; 8():239. PubMed ID: 18706089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
    Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
    Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population.
    Kleibl Z; Havranek O; Hlavata I; Novotny J; Sevcik J; Pohlreich P; Soucek P
    Eur J Cancer; 2009 Mar; 45(4):618-24. PubMed ID: 18996005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer.
    Wasielewski M; Vasen H; Wijnen J; Hooning M; Dooijes D; Tops C; Klijn JG; Meijers-Heijboer H; Schutte M
    Clin Cancer Res; 2008 Aug; 14(15):4989-94. PubMed ID: 18676774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.
    CHEK2 Breast Cancer Case-Control Consortium
    Am J Hum Genet; 2004 Jun; 74(6):1175-82. PubMed ID: 15122511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.
    Bell DW; Kim SH; Godwin AK; Schiripo TA; Harris PL; Haserlat SM; Wahrer DC; Haiman CA; Daly MB; Niendorf KB; Smith MR; Sgroi DC; Garber JE; Olopade OI; Le Marchand L; Henderson BE; Altshuler D; Haber DA; Freedman ML
    Int J Cancer; 2007 Dec; 121(12):2661-7. PubMed ID: 17721994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland.
    Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; van de Wetering T; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2007 Mar; 102(1):119-22. PubMed ID: 16897426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The CHEK2 1100delC variant in Swedish colorectal cancer.
    Djureinovic T; Lindblom A; Dalén J; Dedorson S; Edler D; Hjern F; Holm J; Lenander C; Lindforss U; Lundqvist N; Olivecrona H; Olsson L; Påhlman L; Rutegård J; Smedh K; Törnqvist A; Eiberg H; Bisgaard ML
    Anticancer Res; 2006; 26(6C):4885-8. PubMed ID: 17214356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.